Niagen Bioscience (NAGE) Cash & Current Investments (2013 - 2026)

Niagen Bioscience (NAGE) has reported Cash & Current Investments for 12 consecutive years, with $66.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 19.66% year-over-year to $66.5 million; the TTM figure through Mar 2026 stood at $66.5 million (up 19.66% YoY), while the FY2025 annual figure was $64.8 million, up 45.07% from the prior year.
• Cash & Current Investments improved to $66.5 million in Q1 2026 per NAGE's latest filing, from $64.8 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $66.5 million in Q1 2026 and bottomed at $13.3 million in Q3 2022.
• Historically, Cash & Current Investments has averaged $36.4 million across 5 years, with a median of $27.6 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Current Investments tumbled 59.94% — and 2025, when it jumped 116.87%.
• Niagen Bioscience's Cash & Current Investments stood at $20.4 million in 2022, then soared by 33.68% to $27.3 million in 2023, then jumped by 63.44% to $44.7 million in 2024, then jumped by 45.07% to $64.8 million in 2025, then increased by 2.72% to $66.5 million in 2026.
• Business Quant data shows NAGE's Cash & Current Investments at $66.5 million in Q1 2026, $64.8 million in Q4 2025, and $64.3 million in Q3 2025.